Effect of previous therapies on treatment retention and satisfaction in patients randomized to fingolimod or injectable disease-modifying therapies in PREFERMS

被引：0
|
作者：
Thomas, Florian P. [1 ,2 ]
Hunter, Samuel F. [3 ]
Meng, Xiangyi [4 ]
Schofield, Lesley [4 ]
Kolodny, Scott [4 ]
Tenenbaum, Nadia [4 ]
Cree, Bruce A. C. [5 ]
机构：
[1] Seton Hall Hackensack Meridian Sch Med, S Orange, NJ USA
[2] Hackensack Univ, Med Ctr, S Orange, NJ USA
[3] Adv Neurosci Inst, Franklin, TN USA
[4] Novartis Pharmaceut Corp, E Hanover, NJ USA
[5] UCSF Weill Inst Neurosci, San Francisco, CA USA
来源：
NEUROLOGY | 2018年 / 90卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P1.357
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Satisfaction and Efficacy Outcomes When Switching from Injectable Disease-Modifying Therapies to Fingolimod in PREFERMS: Effect of Previous Treatment
    Hunter, Samuel F.
    Cree, Bruce A. C.
    Meng, Xiangyi
    Schofield, Lesley
    Kolodny, Scott
    Tenenbaum, Nadia
    Thomas, Florian P. P.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 19 - 19
  • [2] Effect of Treatment Naivete on MRI Outcomes with Fingolimod or Injectable Disease-Modifying Therapies in Patients with Multiple Sclerosis: PREFERMS
    Hunter, Samuel F.
    Thomas, Florian P.
    Meng, Xiangyi
    Schofield, Lesley
    Tenenbaum, Nadia
    Cree, Bruce A. C.
    [J]. NEUROLOGY, 2019, 92 (15)
  • [3] Effect of Treatment Naivete on MRI Outcomes with Fingolimod or Injectable Disease-Modifying Therapies in Patients with Multiple Sclerosis: PREFERMS
    Hunter, Samuel F.
    Thomas, Florian P.
    Meng, Xiangyi
    Schofield, Lesley
    Tenenbaum, Nadia
    Cree, Bruce A. C.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 35 - 36
  • [4] Ocrelizumab treatment satisfaction in patients with suboptimal response to previous disease-modifying therapies
    Van Wijmeersch, B.
    Buffels, R.
    Clinch, S.
    Kuhelj, R.
    Wei, W.
    Vermersch, P.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 824 - 825
  • [5] Real-World Patient Retention and Satisfaction on Fingolimod versus Platform Injectable Disease-Modifying Therapies in Early Relapsing-Remitting Multiple Sclerosis; Results from PREFERMS
    Crayton, Heidi
    Steingo, Brian
    Huang, Deren
    Meng, Xiangyi
    Schofield, Lesley
    Johnson, Kristen
    Tenenbaum, Nadia
    [J]. NEUROLOGY, 2016, 86
  • [6] Treatment satisfaction across injectable, infusion, and oral disease-modifying therapies for multiple sclerosis
    Eagle, Tessa
    Stuart, Fiona
    Chua, Alicia S.
    LaRussa, Allison
    Leclaire, Kaitlynne
    Cook, Sandra L.
    Chitnis, Tanuja
    Weiner, Howard L.
    Glanz, Bonnie I.
    Healy, Brian C.
    [J]. MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2017, 18 : 196 - 201
  • [7] TREATMENT - DISEASE-MODIFYING THERAPIES
    LIEBERMAN, JD
    SCHATTEN, S
    [J]. RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 1988, 14 (01) : 223 - 243
  • [8] Treatment satisfaction with injectable disease-modifying therapies in patients with relapsing-remitting multiple sclerosis (the STICK study)
    Fernandez, Oscar
    Duran, Eduardo
    Ayuso, Teresa
    Hernandez, Luis
    Bonaventura, Inmaculada
    Forner, Mireia
    [J]. PLOS ONE, 2017, 12 (10):
  • [9] Key Results fro PREFERMS: Real-World Patient Retention and Outcomes on Fingolimod versus Platform Injectable Disease-Modifying Therapies in Early Relapsing-Remitting Multiple Sclerosis
    Cree, Bruce
    Wynn, Daniel
    Cascione, Mark
    Meng, Xiangyi
    Schofield, Lesley
    Tenenbaum, Nadia
    [J]. NEUROLOGY, 2016, 86
  • [10] Cost-Effectiveness of Injectable Disease-Modifying Therapies in the Treatment of Multiple Sclerosis
    Quach, Jayson
    Dembek, Carole
    Szkurhan, Andrea
    Rashid, Nazia
    Blasco, M. R.
    [J]. NEUROLOGY, 2011, 76 (09) : A474 - A474
12345